Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Metabolic disorders
Biotech
Novo bets up to $354M per target on Gensaic’s delivery tech
Novo will pay up to $354 million per target to work on the tissue-selective delivery of molecules to cardiometabolic targets inside cells.
Nick Paul Taylor
Mar 3, 2025 8:37am
Lilly inks $50M deal for biotech's FXR program
Feb 26, 2025 5:35am
Novo inks $50M metabolic disease pact with genomics biotech
Jan 7, 2025 10:35am
Advantage spins out anti-aging R&D to new biotech Klothea
Nov 25, 2024 11:56am
UPDATE: Lilly-backed metabolic disease biotech files IPO
Sep 4, 2024 10:23am
Marea ropes in $190M for clinical-stage cardiometabolic program
Jun 18, 2024 7:00am
